Bakuchiol
Compiled from published pharmacological and botanical literature. Not independently verified by Herbuno. Spotted an error or have a correction? Flag it below →
| Chemical Class | Meroterpene phenol |
| Molecular Formula / CAS | C₁₈H₂₄O₂ · CAS 10309-37-2 |
| Primary Botanical Source(s) | Babchi / bakuchi seed (Psoralea corylifolia) |
| Plant Part | Seed |
| Typical Content | A major bioactive constituent of babchi seed, standardised commercially up to 99% purity |
| Solubility / Format | Lipophilic phenol; available as high-purity isolate suited to oil-phase cosmetic formulation |
| Sourcing Status | Product-live — genuine match via Herbuno’s babchi seed extract line |
| Buy from Herbuno | Bakuchiol 99% Powder (High-Purity Isolate) · Bakuchiol 98% Powder |
Name origin: Bakuchiol takes its name from “bakuchi,” the Sanskrit and Hindi common name for Psoralea corylifolia, reflecting the compound’s South Asian botanical origin. Traditional use: Babchi seed has a long history in Ayurvedic and Traditional Chinese Medicine, used for skin conditions including vitiligo and psoriasis, as well as for digestive, respiratory and kidney complaints, with topical babchi seed oil specifically associated with skin-repigmentation and skin-health applications long before bakuchiol was isolated as a distinct compound. Research trajectory: Early bakuchiol research through the 1990s and 2000s focused on basic anti-inflammatory and antimicrobial mechanism studies; the field shifted decisively after 2018, when the first head-to-head randomised clinical trial directly compared topical bakuchiol against retinol for facial photoageing, catalysing bakuchiol’s rapid adoption across the cosmetic industry as a plant-derived retinol-alternative active. Commercial source: Babchi seed is the standard commercial source of bakuchiol, and Herbuno’s standardised extract reflects this well-established, genuine botanical match.
Evidence for Bakuchiol Applications
Bakuchiol is a meroterpene phenol that has drawn substantial cosmetic-industry interest as a functional analogue of topical retinoids, inducing similar gene expression changes in skin cells despite having no structural resemblance to vitamin A derivatives. The first randomised, double-blind clinical trial directly comparing the two, a 12-week study in 44 patients applying either 0.5% bakuchiol cream twice daily or 0.5% retinol cream once daily, found bakuchiol comparable to retinol in improving photoageing measures while producing significantly less skin irritation (Dhaliwal et al. 2019). This head-to-head clinical comparison remains the foundational trial behind bakuchiol’s current cosmetic industry positioning. Claim strength: Moderate.
A mechanistic study examining bakuchiol’s multidirectional activity against cellular ageing processes found it exerted antioxidative and anti-inflammatory effects, increased cellular metabolic activity, upregulated extracellular matrix components, and improved epidermal regeneration in both laboratory and clinical testing, concluding that bakuchiol modulates several distinct cellular ageing targets simultaneously rather than acting through a single pathway (et al. 2022). Claim strength: Moderate.
At the molecular level, bakuchiol has been shown to inhibit inducible nitric oxide synthase (iNOS) gene expression through inactivation of nuclear transcription factor-kappaB in LPS- and interferon-gamma-activated macrophages, providing a specific anti-inflammatory mechanism that complements the broader antioxidative and photoageing research (Pae et al. 2001). This mechanistic grounding, published two decades before the clinical retinol-comparison trial, illustrates how bakuchiol’s modern cosmetic application built on a longer-standing basic pharmacology foundation. Claim strength: Moderate.
Bakuchiol has also demonstrated antimicrobial activity relevant to acne, including documented activity against Propionibacterium (Cutibacterium) acnes and other skin-relevant bacteria in laboratory testing, alongside its established anti-inflammatory and antioxidant profile, supporting formulator interest in bakuchiol for acne-adjacent skincare applications distinct from its primary anti-ageing positioning. Claim strength: Moderate.
A systematic review of bakuchiol dermatology literature found the compound has been most extensively studied for photoageing, acne, and post-inflammatory hyperpigmentation, generally showing beneficial results comparable to topical retinoids across the reviewed trials, while noting that although bakuchiol shares no structural similarity to retinoids, it functions as a retinol analogue through retinol-like regulation of skin gene expression. Claim strength: Moderate.
Dosage & Formulator Specification
The clinical trial comparing bakuchiol against retinol used a 0.5% topical concentration applied twice daily, and this concentration range (0.5–1%) is broadly consistent with commercial bakuchiol cosmetic formulation practice; there is no oral/ingestible dosing precedent, as bakuchiol research is concentrated almost entirely on topical dermatological application. Formulators building a serum, cream, or oil product around bakuchiol as the primary active should anchor their inclusion rate to this clinically tested range rather than assuming higher concentrations produce proportionally greater benefit, since the retinol-comparison research specifically validated the 0.5% level.
Analytical quality control for bakuchiol focuses on HPLC purity verification, given its use primarily as a high-purity cosmetic active rather than a standardised whole-extract botanical; formulators should verify purity documentation and stability data specific to their intended formulation base, since bakuchiol’s activity and shelf stability can be affected by the carrier system and packaging used.
Because bakuchiol is derived from Psoralea corylifolia, a plant genus that also contains furanocoumarin (psoralen-type) compounds associated with photosensitising and irritant properties in some preparations, formulators should verify that high-purity bakuchiol isolate sourcing keeps these separate constituents to documented minimal levels, distinct from crude babchi seed extract or oil which may carry a different furanocoumarin profile.
Regulatory positioning for bakuchiol follows established cosmetic ingredient pathways in most markets, given its primary use as a topical cosmetic active rather than an ingestible supplement; formulators should verify current cosmetic ingredient registration status (such as INCI listing and regional cosmetic regulation compliance) for their specific target markets.
Frequently Asked Questions — Bakuchiol
No. Despite functioning as a retinol analogue by inducing similar gene expression changes in skin cells, bakuchiol has no structural resemblance to retinol or other vitamin A derivatives. It is a meroterpene phenol, a chemically distinct class of compound.
A randomised, double-blind, 12-week clinical trial directly compared topical bakuchiol against retinol for facial photoageing and found bakuchiol comparable in efficacy while causing significantly less skin irritation, a finding that has substantially driven its adoption across the cosmetic industry.
No. Research has also documented antimicrobial activity relevant to acne, including activity against Propionibacterium (Cutibacterium) acnes, alongside its anti-inflammatory and antioxidant mechanisms, supporting its use in acne-adjacent skincare applications beyond photoageing.
Psoralea corylifolia, the source plant, also contains furanocoumarin (psoralen-type) compounds associated with photosensitising properties in some preparations. High-purity bakuchiol isolate sourcing keeps these separate constituents to documented minimal levels, distinct from crude seed extract or oil.
Related compounds: Apigenin, Ursolic Acid